Clinical Trials

Facing the biotech cash crunch, Context Therapeutics shelves one drug to double down on two others, a strategic pivot that secures its future into late 2027.

GRAIL’s Galleri test shows stunning clinical results and sales growth, but staggering financial losses and a looming FDA review create a high-wire act for innovation.

Expedition Therapeutics lands a huge Series B and starts a pivotal trial for a drug that could finally target the root cause of COPD for millions.

As Ascentage Pharma preps its mid-year report, we look beyond the balance sheet at the strategic plays and clinical trials fueling its global oncology ambitions.

Compass Pathways is racing towards a 2027 launch for its psilocybin therapy. But can it navigate the complex regulatory and commercial hurdles to deliver on its promise?

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.

Immix Biopharma heads to Morgan Stanley's key conference. Can its promising CAR-T therapy for AL Amyloidosis convince investors to fund the final mile?

Entropy Neurodynamics launches a world-first 'basket study' for its IV psilocin, a high-stakes bet that could redefine mental health treatment pipelines.

A new oral tablet from Entera Bio could replace painful daily injections for millions with severe osteoporosis, a move validated by a top scientific conference.

Healis Therapeutics gets FDA nod for Tyemvers, a botulinum toxin therapy for depression. Can a drug that paralyzes frown muscles disrupt mental healthcare?

After a corporate overhaul and a massive cash infusion, Faeth Therapeutics is pushing its multi-pronged cancer drug PIKTOR toward pivotal clinical data.

An award for a Virginia nurse is more than a headline. It's a signal of a strategic revolution in healthcare, where community clinics become global powerhouses.

Vantage Biosciences has completed enrollment for its oral drug, oruvestat, a potential game-changer for early diabetic retinopathy. This could replace invasive injections.

Oblenio Bio's LBL-051 enters human trials, offering hope for a true "immune reset" and drug-free remission for severe autoimmune disease patients.

IDEAYA Biosciences advances its breakthrough melanoma drug toward FDA review while its $1.24B cash runway fuels a deep pipeline targeting cancer's toughest codes.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

A positive safety review for Molecure's novel sarcoidosis drug OATD-01 de-risks its development, offering new hope for patients and boosting the company's strategic value.

Ceruvia Lifesciences secures $8M for a non-hallucinogenic LSD analog to treat cluster headaches, offering a potential breakthrough for a severe pain disorder.

The nationwide launch of Ritual's prenatal vitamin at Costco is more than a distribution win; it's a stress test for a new retail model based on clinical proof.

As Continual-G expands across the US with bold scientific claims, it highlights a growing trend and a critical question: is this the future of wellness, or just for the wealthy?